Does Rallies show Form 4 insider transactions for BBNX?

Yes. Rallies tracks BBNX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BBNX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BBNX. It does not provide personalized investment advice.

BBNX (Beta Bionics, Inc. Common Stock) Stock Analysis - Insider Trades

Beta Bionics, Inc. Common Stock (BBNX) is a publicly traded Healthcare sector company. As of May 21, 2026, BBNX trades at $10.11 with a market cap of $418.88M and a P/E ratio of 0.00. BBNX moved +7.43% today. Year to date, BBNX is -65.81%; over the trailing twelve months it is -36.17%. Its 52-week range spans $8.80 to $32.71. Analyst consensus is strong buy with an average price target of $19.00. Rallies surfaces BBNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BBNX stock inside the company?

Recent BBNX insider activity includes Hopman Mark sold 353, Hopman Mark sold 834, Russell Steven Jon sold 1.03K, Mensinger Mike sold 1.06K, and Feider Stephen sold 1.43K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BBNX Key Metrics

Key financial metrics for BBNX
Metric	Value
Price	$10.11
Market Cap	$418.88M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$32.71
52-Week Low	$8.80
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Recent BBNX Insider Trades

Hopman Mark sold 353 (~$4.08K) on Mar 4, 2026.
Hopman Mark sold 834 (~$10.31K) on Mar 2, 2026.
Russell Steven Jon sold 1.03K (~$12.68K) on Mar 2, 2026.
Mensinger Mike sold 1.06K (~$13.15K) on Mar 2, 2026.
Feider Stephen sold 1.43K (~$17.65K) on Mar 2, 2026.

Latest BBNX News

Beta Bionics Raises 2026 Guidance to 37–39% Growth, Adds 20 Sales Territories — Apr 22, 2026
Beta Bionics Adds 20 Territories, Targets Patch Pump Launch by 2027 — Mar 6, 2026
Beta Bionics Posts 54% Sales Surge, Boosts Gross Margin to 55.4%, but FDA Warning Weighs — Feb 18, 2026
Beta Bionics Raises 2025 Sales by 54%, Projects $130-135M in 2026 — Feb 17, 2026
Beta Bionics Predicts $30M Q4 Revenue; Analysts See 106.7% Upside — Feb 16, 2026

BBNX Analyst Consensus

8 analysts cover BBNX: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.00.

Common questions about BBNX

Who is trading BBNX stock inside the company?: Recent BBNX insider activity includes Hopman Mark sold 353, Hopman Mark sold 834, Russell Steven Jon sold 1.03K, Mensinger Mike sold 1.06K, and Feider Stephen sold 1.43K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BBNX?: Yes. Rallies tracks BBNX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BBNX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BBNX. It does not provide personalized investment advice.